TG Therapeutics (NASDAQ:TGTX) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08, Briefing.com reports. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter in the previous year, the business earned ($0.34) earnings per share. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded down $0.23 on Wednesday, hitting $20.35. The stock had a trading volume of 3,159,167 shares, compared to its average volume of 3,662,799. The business’s 50-day simple moving average is $18.54 and its two-hundred day simple moving average is $16.57. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of 91.04 and a beta of 2.23. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $23.12. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63.

Analyst Ratings Changes

A number of brokerages recently issued reports on TGTX. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Tuesday. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. LADENBURG THALM/SH SH boosted their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.